The book provides a multidisciplinary and interdisciplinary discussion of the ethos and ethics of precision / personal medicine, involving scientists who have shaped the field, in dialogue with ethicists, social scientists and philosophers of science.

So-called personalized health and precision medicine consist of a plethora of distinct endeavors. Ranging from pharmacogenomics to big data medicine, these endeavors are set out to tailor treatment and prevention to different combinations of data on the biological, behavioral, social, and environmental determinants of health. Currently reaching the trial of implementation across a diverse range of local and national contexts, these innovations call for a thorough empirical scrutiny of the normative, practical, and technical reconfigurations that they engender. Personalized/precision approaches to medicine demand substantive, normative work that consists in reforming social contracts in healthcare, and in ensuring a consistent commitment to change from both institutional actors and citizens.

Doctors, patients, investigators, administrators, and policymakers who assign diagnoses assume three elements: the name describes an entity with conceptual or evidentiary boundaries, the person setting the name has a high degree of certainty, and the name has a consensus definition. This book challenges this practice and offers an alternative to assigning diagnoses: quantitating diagnostic uncertainty in personal and public medical plans. This book offers the stakeholders' views participating in a workshop, sponsored by the Barbara Volcker Center/Hospital for Special Surgery, taking place in April 2020, about uncertain diagnoses. Chapters examine the circumstances in which diagnosis names are "unassignable", either because patients do not fit within diagnostic "boxes" or because health abnormalities evolve and change over time. In addition, the book deconstructs the processes of diagnosis and explores how different stakeholders used diagnosis names for various purposes. In examining pertinent questions, the book offers a roadmap to achieving consensus definitions or including measures of uncertainty in personal care, research, and policy. Diagnoses Without Names: Challenges for Medical Care, Research, and Policy is an essential resource for physicians and related professionals, residents, fellows, and graduate students in internal medicine, rheumatology, and clinical immunology as well as investigators, administrators, policymakers.

Marking its 25th anniversary, this fascinating collection examines the pioneering work of the National Institute for Health and Care Excellence (NICE). Setting standards for the delivery of healthcare, issuing guidance on public health, and assessing and making recommendations on health technologies, NICE has attracted widespread international attention, emulation, and comment. The authors in this collection, drawn from a broad range of disciplinary backgrounds, offer analysis of key issues which have informed NICE’s work, from the principles of health economics, to patient engagement, to the legal basis on which NICE operates. Covering many of the most important themes within contemporary debates on health policy and management today, this insightful collection will interest students and researchers, as well as policy makers in the field.

This work argues that philosophy is not just useful, but vital, for thinking coherently about priorities in health policy and public policy.

This timely Handbook provides an essential guide to the major topics, perspectives, and scholars in the sociology of health and medicine. Contributors prove the immense value of a sociological understanding of central health and medical concerns, including public health, the COVID-19 pandemic, and new medical technologies.

Sex, Gender, and Epigenetics: From Molecule to Bedside explores our expanding knowledge of the science of epigenetics in which gene expression is modified as a consequence of small chemical additions to various components of the genome. The book provides an overview of the field, describing the epigenetic phenomena that unite biological sex and environmental experience to create the unique phenome of each individual. The book also analyzes the impact of ancestors’ environmental experience on subsequent generations through the sex-specific transmission of environmentally induced epigenetic modifications. Here, international leaders in the field discuss both sex-specific normal physiology and the experience of disease, with chapters dedicated to fetal programming, the microbiome, cancer, bipolar disorder and schizophrenia, embryogenesis, and oocyte aging, among other topics. Examines the impact of biological sex and gender on gene expression through epigenetic mechanisms, and its relationship to human biology and disease Presents the current state of our understanding of how environmental experience is translated to future generations in a sex specific manner Features chapter contributions from international leaders in the field

Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates

Medical innovation as it stands today is fundamentally unsustainable. There is a widening gap between what biomedical research promises and the impact that it is currently achieving, in terms of patient benefit and health system improvement. This book highlights the global problem of the ineffective translation of bioscience innovation into health system improvements and its consequences, analyses the underlying causative factors and provides powerful prescriptions for change to close the gap. It contrasts the progress in biomedicine with other areas of scientific and technological endeavour, such as information technology, in which there are faster and more reliable returns for society. The author's career has spanned pharmaceuticals, diagnostics and health informatics and he draws lessons from a host of case examples in which bottlenecks have prevented progress, such as in dementia and antibiotic-resistant infections, and from many in which these barriers have been overcome, such as HIV therapy and targeted cancer treatment. The new era of precision medicine holds the greatest promise of closing this 'innovation gap'. Along with techniques such as open innovation and adaptive development, powerful new genomics and digital health tools are poised to transform the productivity of life sciences. Bioscience-Lost in Translation? lays out a fresh and provocative strategy for advancing the innovation process, shaping the right policy environment and building an ecosystem to deliver the 21st century cures that are urgently needed.